Company History

2007 – 2008: Founded as 4s3 Bioscience by Dustin Armstrong, Ph.D. and Timothy Harris

  • Antibody-targeting technology licensed from UCLA
  • Seed financing provided by Genzyme Ventures

2009 – 2012: Early support through peer-reviewed, competitive funding

  • NIH/R21 grant for Myotonic Dystrophy (DM) POC
  • MDA Grant for Myotubular Myopathy (MTM1) POC
  • Massachusetts State (MLSC) Accelerator Loan

2012: Alopexx $20MM Series A Financing

  • Genzyme participation on minority basis
  • Company name change from 4s3 Bioscience, Inc. to Valerion Therapeutics, LLC
  • $1.2MM preclinical MDA Grant for Myotubular Myopathy

2015: Alopexx $10MM Series B Financing

2016: Alopexx $15MM Series C Financing